Literature DB >> 15094790

Association in Japanese patients between neuroleptic malignant syndrome and functional polymorphisms of the dopamine D(2) receptor gene.

I Kishida1, C Kawanishi, T Furuno, D Kato, T Ishigami, K Kosaka.   

Abstract

A genetic predisposition to the development of neuroleptic malignant syndrome (NMS) has been suggested by clinical studies. Although the molecular basis of NMS is unclear, a dopaminergic blockade mechanism has been considered the main cause. We therefore investigated the association between NMS and three functional polymorphisms of the dopamine D(2) receptor (DRD(2)) gene: TaqI A, -141C Ins/Del, and Ser311Cys. Subjects included 32 Japanese patients, previously diagnosed with NMS, and 132 schizophrenic patients treated with neuroleptics without occurrence of NMS. Polymerase chain reaction and restriction fragment length polymorphism analyses were performed to determine each genotype. We found significant differences in genotypic and allelic frequencies of the -141C Ins/Del polymorphism between patients with and without NMS. The -141C Del allele was significantly more frequent in the NMS group (23.4 vs 11.7%, P=0.026). Similarly, the proportion of -141C Del allele carriers was significantly higher in the NMS group (40.6 vs 20.5%, P=0.022). No significant differences between the two groups were seen for allelic and genotypic frequencies of the TaqI A and Ser311Cys polymorphisms. This result suggests that the -141C Ins/Del polymorphism is likely to predispose toward the development of NMS, probably together with other unidentified factors.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15094790     DOI: 10.1038/sj.mp.4001422

Source DB:  PubMed          Journal:  Mol Psychiatry        ISSN: 1359-4184            Impact factor:   15.992


  9 in total

Review 1.  Genetics and psychopharmacology: prospects for individualized treatment.

Authors:  Charles U Nnadi; Joseph F Goldberg; Anil K Malhotra
Journal:  Essent Psychopharmacol       Date:  2005

Review 2.  Pharmacogenetics in psychiatry: are we ready for widespread clinical use?

Authors:  Maria J Arranz; Shitij Kapur
Journal:  Schizophr Bull       Date:  2008-08-27       Impact factor: 9.306

Review 3.  The promise and reality of pharmacogenetics in psychiatry.

Authors:  Peter P Zandi; Jennifer T Judy
Journal:  Psychiatr Clin North Am       Date:  2010-03

4.  Association of dopamine receptor gene polymorphisms with the clinical course of Wilson disease.

Authors:  T Litwin; G Gromadzka; J Samochowiec; A Grzywacz; A Członkowski; A Członkowska
Journal:  JIMD Rep       Date:  2012-07-06

5.  Updated findings of the association and functional studies of DRD2/ANKK1 variants with addictions.

Authors:  Yunlong Ma; Wenji Yuan; Xianzhong Jiang; Wen-Yan Cui; Ming D Li
Journal:  Mol Neurobiol       Date:  2014-08-20       Impact factor: 5.590

6.  Effects of CYP2D6 polymorphisms on neuroleptic malignant syndrome.

Authors:  Daiji Kato; Chiaki Kawanishi; Ikuko Kishida; Taku Furuno; Kyoko Suzuki; Hideki Onishi; Yoshio Hirayasu
Journal:  Eur J Clin Pharmacol       Date:  2007-08-14       Impact factor: 2.953

7.  Neuroleptic malignant syndrome in an adolescent with CYP2D6 deficiency.

Authors:  Agnieszka Butwicka; Szymańska Krystyna; Włodzimierz Retka; Tomasz Wolańczyk
Journal:  Eur J Pediatr       Date:  2013-11-20       Impact factor: 3.183

8.  Pharmacogenetics of antipsychotic adverse effects: Case studies and a literature review for clinicians.

Authors:  Adriana Foster; Zixuan Wang; Manzoor Usman; Edna Stirewalt; Peter Buckley
Journal:  Neuropsychiatr Dis Treat       Date:  2007-12       Impact factor: 2.570

9.  Evaluation of association of DRD2 TaqIA and -141C InsDel polymorphisms with food intake and anthropometric data in children at the first stages of development.

Authors:  Vanessa Feistauer; Márcia R Vitolo; Paula D B Campagnolo; Vanessa S Mattevi; Silvana Almeida
Journal:  Genet Mol Biol       Date:  2018-07-23       Impact factor: 1.771

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.